港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

68.000

+0.6500.97%

成交量：36.72万

成交额：2,500.59万

市值：135.32亿

市盈率：-39.42

高：68.800

开：67.550

低：67.100

收：67.350

52周最高：83.600

52周最低：63.200

股本：1.99亿

香港流通股本：1.53亿

量比：0.30

换手率：0.24%

股息：- -

股息率：- -

每股收益(LYR):-1.725

净资产收益率：--

总资产收益率：--

市净率：64.34

市盈率(LYR):-39.42

市销率: - -

数据加载中...

总览公司新闻公告

临床开发全面提速！维立志博-B(09887)TCE双抗Ⅰ期疗效比肩CAR-T，Ⅱ期首例患者成功用药

维立志博-B(09887)：LBL-034 II期试验首例患者成功用药

维立志博-B(09887)：稳定价格行动及稳定价格期间结束

中国资产全面爆发！港股打新最高涨近300%

老虎资讯综合

港股异动 | 维立志博(09887)涨超5% 近日奥帕替苏米单抗关键注册临床研究完成全部受试者入组

维立志博-B(09887)因悉数行使超额配股权发行552.93万股

维立志博-B08月11日遭主力抛售527.6万元

累计完成152 起！7月生物医药融资活跃度攀升

26家创新药公司完成新一轮融资！

维立志博-B08月08日遭主力抛售266.0万元

维立志博-B(09887.HK)悉数行使超额配股权

维立志博-B：悉数行使超额配股权，涉及合共552.93万股

医药行业周报：IO2.0赛道进展喜人静待下半年产业催化

创新药还能再买吗？

维立志博-B08月04日主力净流入159.2万元散户资金抛售

一图解码：港股IPO 7月回顾 22家公司递表维立志博上市首日涨超90%

维立志博-B07月31日遭主力抛售1357.8万元

次新股维立志博-B涨超6%，股价突破83港元创上市新高

老虎资讯综合

异动解读 | 维立志博-B股价盘中大涨5.01%，4-1BB双抗平台引发市场关注

异动解读 | 4-1BB双抗概念股热潮延续，维立志博-B盘中大涨5.01%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/09887/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":68,"timestamp":1756109316530,"preClose":67.35,"halted":0,"volume":367200,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-1.725,"marketStatus":"未开盘","change":0.65,"latestTime":"08-25 16:08:36","open":67.55,"high":68.8,"low":67.1,"amount":25005897,"amplitude":0.025241,"askPrice":68.1,"askSize":100,"bidPrice":68,"bidSize":28800,"shortable":0,"etf":0,"ttmEps":-1.651777067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1756171800000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":67.35,"openAndCloseTimeList":[[1756085400000,1756094400000],[1756098000000,1756108800000]],"volumeRatio":0.2973028510468995,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-1.725,"volumeRatio":0.2973028510468995,"shares":199000000,"dividePrice":0,"high":68.8,"amplitude":0.025241,"preClose":67.35,"low":67.1,"week52Low":63.2,"pbRate":"64.34","week52High":83.6,"institutionHeld":0,"latestPrice":68,"committee":0.99308,"eps":-1.725,"divideRate":0,"volume":367200,"delay":0,"ttmEps":-1.651777067,"open":67.55,"prevYearClose":35,"prevWeekClose":67.35,"prevMonthClose":72.15,"prevQuarterClose":35,"fiveDayClose":75.1,"twentyDayClose":73.3,"sixtyDayClose":35,"earningDate":1756396800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-08-22","current":-41.268557,"percent":0.85,"low":-47.422411,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"high":-39.760016,"avg":-43.284558,"sd":2.073186,"marketCap":13022964375},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375}],"updateTime":1756154922449},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562459022","title":"临床开发全面提速！维立志博-B(09887)TCE双抗Ⅰ期疗效比肩CAR-T，Ⅱ期首例患者成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2562459022","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562459022?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 19:08","pubTimestamp":1756120139,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月25日，维立志博-B宣布，公司自主研发的GPRC5D/CD3双特异性抗体顺利完成Ⅱ期临床研究首例患者入组，有望成为首个国产靶向GPRC5D的TCE疗法。LBL-034是一款全球独创2:1结构设计的GPRC5D/CD3双特异性抗体，通过优化抗CD3亲和力和空间位阻作用，显著降低了对T细胞的非特异性激活的风险，同时保持高效的T细胞条件激活能力，从而兼具强大抗肿瘤活性和更佳安全性，具备同类最佳潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4022","BK1161","CAR","BK4230"],"gpt_icon":1},{"id":"2562293248","title":"维立志博-B(09887)：LBL-034 II期试验首例患者成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2562293248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562293248?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:29","pubTimestamp":1756117773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，LBL-034(GPRC5D/CD3双特异性抗体)I期数据亮眼，II期试验首例患者成功用药。这标志着集团LBL-034临床研究取得里程碑成就，为推进后续临床试验奠定坚实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2561469612","title":"维立志博-B(09887)：稳定价格行动及稳定价格期间结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2561469612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561469612?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 18:40","pubTimestamp":1755772837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，有关全球发售的稳定价格期间于2025年8月21日(星期四)结束。于稳定价格期间，稳定价格操作人并无在市场上买卖任何H股以稳定价格。紧随稳定价格期间结束后，公司将继续遵守上市规则第19A.13A条的公众持股量规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1141757368","title":"中国资产全面爆发！港股打新最高涨近300%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141757368","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141757368?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 11:05","pubTimestamp":1755572712,"startTime":"0","endTime":"0","summary":"8月19日，中国资产全面爆发，A股沪指创近10年新高！港股IPO持续势如破竹，7月以来上市12支，首日10支收涨，2支收跌，胜率高达83.33%！累计一手收益可达15,367港元。📢 双登股份（06960）正在火热申购中🔥🚩 申购方式：【老虎国际App】-【持仓】-【IPO】✨ 老虎打新优势：✅ 现金申购0手续费，融资申购0孖展利息✅ 10倍杠杆，额度充足✅ 支持暗盘交易，快人一步抢占先机✅ TOP科技券商，安全可靠","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"中国资产全面爆发！港股打新最高涨近300%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","02627","06960","02591"],"gpt_icon":0},{"id":"2560745809","title":"港股异动 | 维立志博(09887)涨超5% 近日奥帕替苏米单抗关键注册临床研究完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2560745809","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560745809?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 14:34","pubTimestamp":1755498852,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博涨超5%，截至发稿，涨4.54%，报72.5港元，成交额8642.91万港元。消息面上，据维立志博官微消息，8月14日，公司宣布，奥帕替苏米单抗单臂关键注册临床研究已完成全部受试者入组。据介绍，奥帕替苏米单抗是一种PD-L1与4-1BB双靶向双特异性抗体，为全球首款已处于单臂关键性临床阶段的靶向共刺激受体4-1BB的分子，有望成为治疗EP-NEC的首款获批药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":1},{"id":"2558665686","title":"维立志博-B(09887)因悉数行使超额配股权发行552.93万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665686","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558665686?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 17:49","pubTimestamp":1754905773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年8月11日根据悉数行使超额配股权而发行及配发552.93万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1328075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2558658118","title":"维立志博-B08月11日遭主力抛售527.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558658118","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558658118?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 16:15","pubTimestamp":1754900157,"startTime":"0","endTime":"0","summary":"08月11日, 维立志博-B股价跌3.27%，报收66.50元，成交金额8624.9万元，换手率0.85%，振幅7.42%，量比1.04。维立志博-B今日主力资金净流出527.6万元，连续3日净流出，上一交易日主力净流出266.0万元。该股近5个交易日下跌6.99%，主力资金累计净流出463.6万元；近20日主力资金累计净流出572.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811170043a6df4922&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811170043a6df4922&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":1},{"id":"2558638949","title":"累计完成152 起！7月生物医药融资活跃度攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2558638949","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558638949?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 09:34","pubTimestamp":1754876074,"startTime":"0","endTime":"0","summary":"2025 年 7 月，全球生物医药领域迎来了融资热潮，交出了一份亮眼的 “成绩单”。数据统计显示，当月共计完成融资活动 152 起，累计公开披露的融资总额超过 43 亿美元，展现出该领域强劲的发展活力与资本吸引力。值得关注的是，在这 26 家企业中，不乏多家国内药企的身影，彰显了中国生物医药企业在创新领域的崛起之势。如橙帆医药7月28日宣布完成超6000万美元的Pre-A+轮融资。维立志博7月25日在香港交易所主板正式挂牌上市，募资总额约1.89亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081109365694dbbc03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081109365694dbbc03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592","09887"],"gpt_icon":0},{"id":"2558508550","title":"26家创新药公司完成新一轮融资！","url":"https://stock-news.laohu8.com/highlight/detail?id=2558508550","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558508550?lang=zh_cn&edition=fundamental","pubTime":"2025-08-09 07:17","pubTimestamp":1754695052,"startTime":"0","endTime":"0","summary":"根据药明康德数据库统计，截至2025年7月31日，2025年7月全球生物医药领域共计完成152起融资活动，累计公开披露的融资总额超过了43亿美元。其中，有26家专注于开发创新疗法的公司完成的单笔融资额突破了5000万美元大关。CoRegen：细胞疗法研发公司7月9日，CoRegen宣布完成9339万美元的融资。Nuclidium：放射性治疗和诊断药物研发公司7月10日，Nuclidium宣布成功完成7900万瑞士法郎B轮融资，用于推进铜基放射性药物平台临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809072255a6dbb9f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809072255a6dbb9f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","02592","BK1574","06978"],"gpt_icon":0},{"id":"2557716524","title":"维立志博-B08月08日遭主力抛售266.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557716524","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557716524?lang=zh_cn&edition=fundamental","pubTime":"2025-08-08 16:15","pubTimestamp":1754640934,"startTime":"0","endTime":"0","summary":"08月08日, 维立志博-B股价跌2.83%，报收68.75元，成交金额4917.2万元，换手率0.48%，振幅4.24%，量比0.46。维立志博-B今日主力资金净流出266.0万元，上一交易日主力净流出469.9万元。该股近5个交易日下跌1.71%，主力资金累计净流入223.2万元；近20日主力资金累计净流出45.2万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173825a6dac125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173825a6dac125&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2557586428","title":"维立志博-B(09887.HK)悉数行使超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2557586428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557586428?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 07:52","pubTimestamp":1754524348,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2557585220","title":"维立志博-B：悉数行使超额配股权，涉及合共552.93万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557585220","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557585220?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 07:45","pubTimestamp":1754523930,"startTime":"0","endTime":"0","summary":"格隆汇8月7日丨维立志博-B(09887.HK)发布公告，招股章程所述超额配股权已于2025年8月6日(星期三)由整体协调人(为其本身及代表国际包销商)悉数行使，涉及合共552.93万股股份，占全球发售项下可供认购发售股份总数约15%(经计及发售量调整权获悉数行使，惟于任何超额配股权获行使前)。超额配发股份将由公司按每股35.00港元发行及配发。超额配发股份将用于加快向同意其根据全球发售认购的相关H股延迟交付的承配人交付部分H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080707465094d45892&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080707465094d45892&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2557964733","title":"医药行业周报：IO2.0赛道进展喜人 静待下半年产业催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2557964733","media":"爱建证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557964733?lang=zh_cn&edition=fundamental","pubTime":"2025-08-05 00:00","pubTimestamp":1754323200,"startTime":"0","endTime":"0","summary":"医药板块本周+2.95%，排名1/31，跑赢沪深300 指数，创新药依然是板块重心。市场短期冲高回调，静待下半年创新药产业催化。IO 2.0 赛道进展喜人，下半年继续重点关注。1）基石药业：计划在ESMO 2025 大会公布全球首款PD-1 三抗的临床研究数据。4）中国生物制药：礼新医药与默沙东合作开发LM-299 进展顺利，7 月已完成技术转移，预计三季度将收到3 亿美金技术转移里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805194354a4768bf3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805194354a4768bf3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1997245094.SGD","09606","LU1997244956.HKD","LU1997245177.USD","02157","01877","LU1979443071.USD","09887","06821","BK0216","02696","SBHMY","09926","LU2495084118.USD","688331","09995","02616","688180","603259","688520","01541","01177","LU2328871848.SGD","01093","LU0456842615.SGD","LU1969619763.USD","LU2488822045.USD","06990","688062","LU1934453819.USD","02268"],"gpt_icon":0},{"id":"2556807450","title":"创新药还能再买吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2556807450","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556807450?lang=zh_cn&edition=fundamental","pubTime":"2025-08-04 17:41","pubTimestamp":1754300474,"startTime":"0","endTime":"0","summary":"另外，部分创新药个股实现翻倍增长。但是，站在当下节点，创新药还能再买吗？其担忧可总结为三点：第一，中国创新药同质化严重，将演变为内卷式竞争。同时，BD交易时，中国创新药资产可能会被低估，从而影响创新药企业的受益。对于上述担忧，我们认为中国创新药市场整体处于高点，但还存在着更多潜力资产。毫无疑问，参与内卷式竞争的创新药企业存在较高的投资风险。尽管如此，诸多创新药企业仍在通过多种方式进行差异化布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804174436a4742b9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804174436a4742b9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2495084118.USD","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","BK0196","BK0060","BK0028","LU2580892862.HKD","06996","LU1655091616.SGD","BK0183","01877","BK0239","LU0405327494.USD","01276","LU1328615791.USD","09887","02696","LU1064131003.USD","LU2580892789.USD","688180","LU1997244956.HKD","688520","159992","BK0012","01530","688235","06160","LU2148510915.USD","09688","LU1969619763.USD","02142","LU2488822045.USD","LU2328871848.SGD","01801","BK0188","600276","01672","688506","09926","LU1064130708.USD"],"gpt_icon":0},{"id":"2556709802","title":"维立志博-B08月04日主力净流入159.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2556709802","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556709802?lang=zh_cn&edition=fundamental","pubTime":"2025-08-04 16:15","pubTimestamp":1754295354,"startTime":"0","endTime":"0","summary":"08月04日, 维立志博-B股价涨2.14%，报收71.50元，成交金额1.2亿元，换手率1.12%，振幅5.71%，量比0.47。维立志博-B今日主力资金净流入159.2万元，上一交易日主力净流出700.3万元。该股近5个交易日下跌2.46%，主力资金累计净流出1519.6万元；近20日主力资金累计净流出109.3万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804165624a6d20415&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804165624a6d20415&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2556800709","title":"一图解码：港股IPO 7月回顾 22家公司递表 维立志博上市首日涨超90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556800709","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556800709?lang=zh_cn&edition=fundamental","pubTime":"2025-08-04 09:35","pubTimestamp":1754271354,"startTime":"0","endTime":"0","summary":"7月港股IPO市场较上月稍显平静。2025年7月，港股IPO市场共有22家公司递交了上市申请，其中包括老乡鸡、星源材质（300568.SZ）、澜起科技（688008.SH）、歌尔微电子、欣旺达（300207.SZ）和云天励飞（688343.SH）等；同时，有9家公司完成敲钟，成功登陆港交所。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/bc1ee1d5-7dd2-41ac-b729-16cd81c42b79.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/bc1ee1d5-7dd2-41ac-b729-16cd81c42b79.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68900e7a230829fb12e1a375","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK4614","09887","HSTECH","07226","BK1161","YANG","HSCEI"],"gpt_icon":0},{"id":"2555838257","title":"维立志博-B07月31日遭主力抛售1357.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555838257","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555838257?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 16:15","pubTimestamp":1753949744,"startTime":"0","endTime":"0","summary":"07月31日, 维立志博-B股价跌5.87%，报收72.15元，成交金额1.8亿元，换手率1.65%，振幅10.83%，量比0.00。维立志博-B今日主力资金净流出1357.8万元，上一交易日主力净流出1195.2万元。该股近5个交易日上涨105.86%，主力资金累计净流入431.8万元；近20日主力资金累计净流入431.8万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170720a46d35b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170720a46d35b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":0},{"id":"1189249429","title":"次新股维立志博-B涨超6%，股价突破83港元创上市新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1189249429","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189249429?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 09:57","pubTimestamp":1753840623,"startTime":"0","endTime":"0","summary":"7月30日，次新股$维立志博-B(09887)$涨超6%，股价突破83港元创上市新高。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8373fc8f0693d3cb43ea2979da82ba81","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"次新股维立志博-B涨超6%，股价突破83港元创上市新高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1100114192","title":"异动解读 | 维立志博-B股价盘中大涨5.01%，4-1BB双抗平台引发市场关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1100114192","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100114192?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 09:54","pubTimestamp":1753840479,"startTime":"0","endTime":"0","summary":"维立志博-B今日盘中大涨5.01%，引发市场广泛关注。该公司作为一家专注于创新生物技术的企业，近期在4-1BB双抗体平台方面的进展可能是推动股价上涨的主要原因。据悉，维立志博-B的核心产品LBL-024是一种PD-L1 x 4-1BB双特异性抗体，属于第二代免疫肿瘤疗法的差异化技术路线。值得注意的是，维立志博-B在攻克4-1BB靶点的研发壁垒方面取得了突破。随着公司继续推进临床试验并发布更多数据，市场对维立志博-B的关注度可能会进一步提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"gpt_icon":1},{"id":"1149859553","title":"异动解读 | 4-1BB双抗概念股热潮延续，维立志博-B盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149859553","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149859553?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 09:54","pubTimestamp":1753840478,"startTime":"0","endTime":"0","summary":"7月30日周三盘中，港股上市公司维立志博-B股价出现显著上涨，截至上午9时52分，该股涨幅达到5.01%。维立志博-B是一家专注于创新药物研发的生物科技公司，其核心产品管线包括备受市场关注的4-1BB双抗药物。分析人士认为，维立志博-B今日的股价上涨可能与市场对4-1BB双抗药物持续看好有关。随着更多投资者认识到这一创新疗法的潜力，以及公司在该领域的领先地位，维立志博-B的股价可能会继续受到追捧。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}